News from CROI 2013

The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) took place at the Georgia World Congress Center in Atlanta, USA, in early March 2013.

We reported on key research presented at the conference, publishing news and sending out summary bulletins by email, three during the conference week and one the following week.

CROI is a scientific conference, bringing together around 4000 researchers and doctors to share their work and debate current issues. As well as publishing abstracts and posters on the official conference website, the conference organisers film key sessions and produce webcasts, so you can watch presentations online. They aimed to make around 90% of the conference available online and we included relevant links in our news stories and bulletins.

“The coverage made me feel I was at the conference and I appreciate NAM's effort in sharing the bulletins.” NAM bulletin subscriber

aidsmap news from CROI 2013

Self-testing and home treatment initiation triples uptake of HIV treatment in Malawi

Offering people the opportunity to self-test at home and then start antiretroviral therapy after counselling at home, together with home delivery of antiretroviral drugs, increased the number

Published
21 March 2013
By
Keith Alcorn
Sofosbuvir plus ribavirin works well for hard-to-treat inner-city hepatitis C patients

A simple 24-week oral regimen consisting of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 hepatitis C, many of whom had

Published
20 March 2013
By
Liz Highleyman
AbbVie interferon-free combinations cure most newly treated hepatitis C patients

All-oral regimens consisting of the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor and ribavirin led to sustained response for more than 90% of previously untreated hepatitis 

Published
20 March 2013
By
Liz Highleyman
Are we underestimating the proportion of virally-suppressed patients in the US?

Several presentations at the recent 20th Conference on Retroviruses and Opportunistic Infections in Atlanta suggest that previous estimates of the proportion of people with HIV in the

Published
15 March 2013
By
Gus Cairns
Lopinavir/ritonavir equivalent to nevirapine in Ugandan children

A ritonavir-boosted lopinavir (LPV/r)-based regimen achieved a comparable rate of virologic suppression when compared to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen in HIV-infected Ugandan children at 48

Published
14 March 2013
By
Carole Leach-Lemens
Gene therapy studies show potential for HIV control without drugs

Gene therapy approaches that involve the genetic modification of human haematopoietic stem cells have the potental to engineer HIV control by introducing cells resistant to

Published
13 March 2013
By
Gus Cairns
Adding telaprevir improves acute hepatitis C treatment for HIV-positive men

Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and increases the likelihood of a cure for HIV-positive men with acute

Published
12 March 2013
By
Liz Highleyman
Simeprevir & sofosbuvir demonstrates good early cure rate with or without ribavirin

An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C

Published
12 March 2013
By
Liz Highleyman
Malawi achieves seven-fold increase in ART for pregnant and breastfeeding women

Eighteen months after implementation of 'Option B+' in Malawi – ART for life for all HIV-infected, pregnant or breastfeeding women regardless of CD4 count or disease

Published
12 March 2013
By
Carole Leach-Lemens
Routine viral load monitoring almost halves risk of virologic failure in 18-month Kenyan study

Six-monthly viral load testing of patients taking antiretroviral therapy (ART) at primary health clinics in rural Kenya reduced the risk of virologic failure at 18 months of

Published
12 March 2013
By
Lesley Odendal
← First123...4Next →

Subscribe now

Sign up for our regular email bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

aidsmap news iPhone app

Keep up to date with the latest HIV news using the free aidsmap news iPhone app.

Download the app >

    NAM is partnering with gTt (Barcelona), GAT (Lisbon) and LILA (Como) to deliver the CROI 2013 bulletins, which have also been made possible thanks to support from Bristol-Myers Squibb. NAM’s wider conference news reporting services have been supported by Abbott, Boehringer Ingelheim, Janssen, Roche and ViiV Healthcare. The funders have no editorial control over the content of the materials.